The Sahajanand Medical Technologies Limited Date Will Be Updated Soon .
Sahajanand Medical Technologies has filed an initial public offering (IPO) with SEBI for Rs. 1,500 crore. The IPO includes a new issuance of Rs.410.33 crore and an offer to sell equity shares worth Rs.1,089.67 crore. Dhiraj Kumar S Vasoya is selling shares worth Rs.100 crore, Shree Hari Trust is selling shares worth Rs.33.75 crore, Samara Capital Markets Holding is selling shares worth Rs.635.56 crore, and NHPEA Sparkle Holding BV is selling shares worth Rs.320.36 crore.
Start your investing journey today. How do you open your own demat account for free?
Bidding Dates
Coming Soon
Price Range
₹0 per share
Face Value
₹0 per share
GMP
₹0
Sahajanand Medical Technologies Limited GMP
The Sahajanand Medical Technologies Limited IPO GMP is ₹[].
IPO Overview
Sahajanand Med Tech has filed for an IPO with SEBI worth Rs.1,500 crore. The IPO comprises a fresh issue worth Rs.410.33 crore and an offer to sell equity shares worth Rs.1,089.67 crore. The offer for sale consists of the sale of shares worth Rs.100 crore by DhirajKumar S Vasoya, Shree Hari Trust is offloading shares worth Rs.33.75 crore, and Samara Capital Markets Holding is offloading Rs.635.56 crore worth of shares, NHPEA Sparkle Holding BV is offloading shares worth Rs.320.36 crore.
Sahajanand Medical Technologies Financials
| Particulars | FY2021 | FY20 | FY19 |
| Revenue | 588.52 | 479.9 | 326.11 |
| PAT | 72.38 | 25.43 | 25.43 |
| EPS | 8.13 | 2.69 | 3.67 |
| Total Assets | 861.95 | 631.78 | 520.36 |
| Total Borrowings | 325.10 | 87.21 | 69.64 |
| Equity Share Capital | 8.89 | 8.89 | 8.89 |
Sahajanand Medical Technologies Limited Peer Comparison
| Particulars (In USD Mn) | Medtronic | Boston Scientific | Abbott | Edwards Life Science |
| Revenue | 30,117 | 9,913 | 34,608 | 4,386 |
| EBITDA | 8,236 | 1,723 | 8,618 | 1,431 |
| EBITDA Margin | 27.35% | 17.38% | 24.90% | 32.63% |
| ROE | 7.06 | 0.56 | 13.93 | 18.88 |
| Net Income Margin | 12% | 0.83% | 12.86% | 18.77% |
| Debt to Equity | 53.29 | 62.73 | 60.67 | 15.19 |
Company Profile
Sahajanand Medical Tech, founded in 2001, is a prominent medical device company focusing on the worldwide research, development, production, and marketing of vascular devices. In FY21, they maintained a 31% market share in the drug-eluting stent market in India. Sahajanand was among the top five corporations in market share in countries such as Germany, the Netherlands, Poland, and Italy as of March 31, 2021. They sell and distribute their products in 69 countries worldwide. Their products are used in interventional cardiology, structural heart therapy, and peripheral intervention. Their three research and development centres are in Surat, Galway, Ireland, and Nonthaburi, Thailand.
Sahajanand Medical Technologies has 67 patents worldwide, with 17 more in the process and four design registrations in India. As of March 31, 2021, the firm has 946 full-time employees, 410 contract employees, and 24 consultants. Their sales team comprises 131 salespeople distributed over 37 sites. Sterling AddLife India Pvt Ltd, Fortis Hospitals, Max Hospitals, and Paras Hospitals are some of Sahajanand Med Tech’s most notable clients.
IPO Strenghts
- Experienced promoters and a competent management team.
- Well-established relationships with a loyal customer base.
- Access to markets worldwide, enabling global reach.
IPO Weakness
- Heavy reliance on customers based in the United States.
- Need to adhere to multiple laws and regulations in these countries to ensure compliance.
- Competition from other players in the market.
